– UK, London – Quell Therapeutics, a new cell therapy company, is announced today starting from the foundation with a £35 million commitment in a Series A financing from Syncona Ltd of which Syncona has committed £34m with a further £1m being contributed by UCL Technology Fund. Syncona will have a 69.3 percent stake1 in the business, with the first tranche of the Series A commitment of £8.3m paid in May 2019.
Quell has been established with the aim of developing engineered T regulatory cell therapies. Tregs are a subset of T cells that provide a regulatory function that harnesses their strong immune-suppressive capacity. Quell will seek to utilise the power of Treg cells to advance therapies for the management and treatment of a range of conditions such as solid organ transplant rejection, autoimmune and inflammatory diseases.
Syncona has significant domain expertise in the T-cell field and identified Treg cells as an area of high interest in late 2017 and sought to form a company in this emerging area. As part of the process, Syncona identified global key opinion leaders and unified them behind a common goal of building a company to treat conditions of immune dysfunction utilising gene-modified cells. As a result, Quell has been founded in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases from Kings College London, UCL, and Hannover Medical School.
The £35 million financing will allow the company to initiate the development of its first programme. The Syncona team will work closely with Quell as it builds out its operations and management team. Syncona Chief Executive, Martin Murphy, has been appointed Chairman, whilst Elisa Petris and Freddie Dear, Syncona Partners, will be Director and Observer on the Board, respectively.
Elisa Petris, Partner of Syncona Investment Management Limited, said: “The foundation of Quell represents an exciting opportunity for Syncona to build the leading cell engineering company with the potential to develop a first-in-class therapy in an innovative field. Over the last year, we have worked to bring together a group of world-class leaders in their respective fields, developed a strategy for the business and funded the business to enable it to scale and succeed. We look forward to continuing to work in close partnership with them as we build out the company’s management team and business plan to deliver their goal of becoming the leader in treating conditions of immune dysfunction utilising gene-modified cells.”
Martin Murphy, Chief Executive of Syncona Investment Management Limited, said: “Quell is the tenth life science company to be founded by Syncona and clearly demonstrates our proactive model in areas of deep domain expertise. We identified an innovative area of science with the potential to deliver dramatic impact for patients and worked to build a company around it. It is an exciting addition to our cell therapy platform, where we are strategically and uniquely positioned with expertise across a range of modalities.”
Professor Alberto Sanchez-Fueyo of Kings College London, Founding Partner, said: “We are delighted to partner with Syncona to found Quell and are excited to work with the team to develop the next generation of engineered Treg cell therapies. The founder team has a unique cross-section of expertise, built over decades of scientific research and we believe there is a significant opportunity to develop novel therapies for the treatment of solid organ transplant and autoimmune conditions. We share Syncona’s vision to bring products to patients in areas of high unmet medical need and are looking forward to the journey ahead.”
Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at UCL, said: “Quell brings together the expertise in clinical trials, regulatory T cell biology, and gene engineering at UCL, King’s College London and Hannover Medical School. It is exciting to have the backing of Syncona to develop a new class of living medicine to avoid transplant rejection and treat autoimmune diseases.”
About Syncona
Syncona is a leading FTSE250 healthcare company focused on founding, building and funding global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.
We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses.
We take a long-term view, underpinned by a deep pool of capital, and are established leaders in gene and cell therapy. We focus on delivering dramatic efficacy for patients in areas of high unmet need.
About Quell Therapeutics
Quell’s vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next-generation engineered T-regulatory cell therapies for a range of solid organ transplant and autoimmune conditions.
Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanni Lombardi, Professor of Human Transplant Immunology at Kings College London, Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London, Emma Morris, Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader “Immune tolerance” in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.
Syncona is a London listed FTSE 250 healthcare company, which has committed £34 million to the business in a £35 million Series A financing, with a further £1.0 million being contributed by UCL Technology Fund.
About UCL Technology Fund
The UCL Technology Fund is dedicated to investing in intellectual property commercialisation opportunities arising from UCL’s world-class research base, focusing in particular on the physical and life sciences. The Fund supports UCL in achieving the full potential of innovations that have prospects for outstanding societal and market impact, right through the development journey from initial proof of concept to practical commercial application.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
